Compare Ascendis Pharma A/S (ASND) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Main Street Capital Corporation — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Main Street Capital Corporation trades at $59 (market cap $5.47B). The key difference: Ascendis Pharma A/S is far larger — about 3.1× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 5.43% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MAIN | |
|---|---|---|
Market Cap | $16.78B | $5.47B |
Sector | Health | Financials |
52-Week High | $277.18 | $67.54 |
52-Week Low | $189.74 | $49.63 |
Enterprise Value | $17.15B | — |
Dividend Yield | — | 5.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
Main Street Capital (MAIN) trades at $58.94, up 3.79% with strong technical momentum. The stock shows bullish technical signals with support at $57 and resistance at $60. Recent Q2 2026 earnings beat expectations at $0.97 per share, though Q1 missed. The company maintains an 80.77% net income margin with consistent dividend payments, positioning it as a reliable income stock. Revenue trends show slight moderation from 2024's peak but remain above 2022-2023 levels.
Outlook remains positive given MAIN's strong profitability and dividend consistency, though near-term risks include expense pressures impacting earnings coverage and broader market volatility. Analyst consensus leans cautious with 78.57% hold ratings, suggesting limited upside from current levels despite the stock's technical strength and income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
